Tag: crohn’s disease CD treatment industry analysis

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Market Value Expansion Is Expected For The Crohn’s Disease (CD) Treatment Market Over The Forecast Period?

The crohn’s disease (cd) treatment market has shown consistent expansion in recent years. This market is projected to increase from $12.32 billion in 2025 to $12.88 billion in 2026, achieving a compound annual growth rate (CAGR) of 4.5%. Historically, this growth was influenced by factors including the increasing prevalence of inflammatory bowel disease, the limitations inherent in conventional corticosteroids, disease management primarily centered in hospitals, prevalent delayed diagnosis rates, and a significant reliance on immunomodulators.

The crohn’s disease (cd) treatment market is projected to experience robust expansion in the coming years. This market is anticipated to reach a valuation of $16.01 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.6%. Key factors contributing to this anticipated growth include advancements in biologics development, the rise of precision medicine, heightened patient awareness, enhanced diagnostic techniques, and increased access to specialty gastroenterology care. Significant trends observed during the forecast period encompass the increasing use of biologic therapies, the proliferation of targeted small molecule drugs, a heightened focus on achieving long-term disease remission, the evolution of personalized treatment approaches, and the integration of combination therapy regimens.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12902&type=smp

Which Growth Factors Are Strengthening The Crohn’s Disease (CD) Treatment Market Landscape?

The escalating occurrence of inflammatory bowel diseases is projected to drive the expansion of the Crohn’s disease (CD) treatment market moving forward. Inflammatory bowel disease (IBD) encompasses a group of chronic inflammatory disorders that predominantly affect the gastrointestinal (GI) tract. Treatment for Crohn’s disease (CD) provides symptom alleviation, lessens inflammation, promotes periods of remission, and improves the overall quality of life for those afflicted with this chronic inflammatory bowel condition. For instance, in September 2023, the United States National Library of Medicine, a medical library based in the US, reported that in Canada, the incidence of inflammatory bowel diseases (IBD) was an estimated 30 per 100,000 person years in 2023, with projections indicating a consistent annual increase of approximately 0.58%. By 2023, the prevalence of IBD in Canada had reached about 825 per 100,000, and forecasts suggest this could climb to 1.1% of the population by 2035. Consequently, the rising prevalence of inflammatory bowel diseases propels the Crohn’s disease (CD) treatment market.

Which Segment Divisions Form The Structure Of The Crohn’s Disease (CD) Treatment Market?

The crohn’s disease (cd) treatment market covered in this report is segmented –

1) By Drug Type: Antibiotics, Amino Salicylates, Corticosteroids, Immunomodulators, Other Drug Types

2) By Route Of Administration: Oral, Injectable

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores

Subsegments:

1) By Antibiotics: Metronidazole, Ciprofloxacin, Rifaximin

2) By Amino Salicylates: Mesalamine, Sulfasalazine

3) By Corticosteroids: Prednisone, Budesonide, Hydrocortisone

4) By Immunomodulators: Azathioprine, Mercaptopurine, Methotrexate

5) By Other Drug Types: Biologic Therapies, Janus Kinase Inhibitors, Small Molecules

What Trends Are Influencing The Future Of The Crohn’s Disease (CD) Treatment Market?

Leading companies in the Crohn’s disease (CD) treatment market are increasingly focusing on developing advanced technologies, such as non-invasive biomarker-based diagnostic platforms. These innovations aim to improve disease detection, enhance monitoring accuracy, and support personalized treatment decisions. Non-invasive diagnostic technologies in Crohn’s disease refer to tools that analyze biological samples without requiring invasive procedures, enabling earlier identification of inflammation, better tracking of disease activity, and an improved patient experience. For instance, in March 2023, The IRR Chemistry Hub, a Scotland-based interdisciplinary research center, developed IBDSENSE, a fluorescence-based technology designed to enhance diagnosis and monitoring of inflammatory bowel disease, including Crohn’s disease. This platform measures the enzyme activity of Granzyme B (GzmB) in patient biosamples, offering a patient-friendly, non-invasive method to assess disease progression and inform therapeutic choices.

Who Are The Businesses Driving Activity In The Crohn’s Disease (CD) Treatment Market?

Major companies operating in the crohn’s disease (cd) treatment market are AbbVie Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited, Novartis AG, Amgen Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Mylan N.V., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Amneal Pharmaceuticals LLC, Ferring B.V., Eli Lilly and Company, Sanofi S.A., Bristol-Myers Squibb Company, Galapagos NV, Abivax, Biogen Inc., Gilead Sciences, RedHill Biopharma, Prometheus Biosciences, Hoffmann‑La Roche

Access The Complete Crohn’s Disease (CD) Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/crohns-disease-cd-treatment-global-market-report

Which Region Accounts For The Highest Share Of The Crohn’s Disease (CD) Treatment Market?

North America was the largest region in the Crohn’s disease (CD) treatment market in 2025. The regions covered in the crohn’s disease (cd) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Crohn’s Disease (CD) Treatment Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=12902&type=smp

Browse Through More Reports Similar to the Global Crohn’s Disease (CD) Treatment Market 2026, By The Business Research Company

Acute Ischemic Stroke Diagnosis Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/acute-ischemic-stroke-diagnosis-global-market-report

Acute Ischemic Stroke Drugs Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/acute-ischemic-stroke-drugs-global-market-report

Myocardial Ischemia Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/myocardial-ischemia-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Does The Market Size Of The Crohn’s Disease (CD) Treatment Market Compare Between 2026 And 2030?

The crohn’s disease (cd) treatment market size has seen consistent growth over recent years. Its valuation is anticipated to rise from $12.32 billion in 2025 to $12.88 billion in 2026, advancing at a compound annual growth rate (CAGR) of 4.5%. The expansion observed in prior periods stemmed from factors including the increasing prevalence of inflammatory bowel disease, the recognized limitations of conventional corticosteroids, a management approach centered on hospitals, persistent delayed diagnosis rates, and a significant reliance on immunomodulators.

The crohn’s disease (cd) treatment market size is projected to experience substantial expansion over the next few years. It is forecast to grow to $16.01 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.6%. This expected growth can be attributed to advancements in biologics development, the proliferation of precision medicine, increased patient awareness, refined diagnostic techniques, and enhanced specialty gastroenterology care. Prominent trends anticipated in this period include the rising utilization of biologic therapies, the expansion of targeted small molecule drugs, a heightened focus on achieving long-term disease remission, the development of personalized treatment approaches, and the integration of combination therapy regimens.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/crohns-disease-cd-treatment-global-market-report

Which Key Factors Are Driving The Crohn’s Disease (CD) Treatment Market Growth?

The future expansion of the Crohn’s disease (CD) treatment market is anticipated due to the rising occurrence of inflammatory bowel diseases. Inflammatory bowel disease (IBD) encompasses a range of persistent inflammatory conditions predominantly impacting the gastrointestinal (GI) system. Treatment for Crohn’s disease (CD) provides symptom alleviation, diminishes inflammation, fosters disease remission, and improves the overall well-being of those affected by chronic inflammatory bowel disease. As an illustration, a September 2023 assessment by the United States National Library of Medicine, a medical library located in the US, determined that in Canada, the incidence of inflammatory bowel diseases (IBD) stood at an estimated 30 per 100,000 person years in 2023, with forecasts showing a consistent annual rise of around 0.58% per year. By 2023, the widespread occurrence of IBD in Canada had reached approximately 825 per 100,000, and predictions indicate a potential increase to 1.1% of the population by 2035. Consequently, the growing prevalence of inflammatory bowel diseases is a key factor propelling the Crohn’s disease (CD) treatment market.

How Are Different Segments Classified In The Crohn’s Disease (CD) Treatment Market Segment Analysis?

The crohn’s disease (cd) treatment market covered in this report is segmented –

1) By Drug Type: Antibiotics, Amino Salicylates, Corticosteroids, Immunomodulators, Other Drug Types

2) By Route Of Administration: Oral, Injectable

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores

Subsegments:

1) By Antibiotics: Metronidazole, Ciprofloxacin, Rifaximin

2) By Amino Salicylates: Mesalamine, Sulfasalazine

3) By Corticosteroids: Prednisone, Budesonide, Hydrocortisone

4) By Immunomodulators: Azathioprine, Mercaptopurine, Methotrexate

5) By Other Drug Types: Biologic Therapies, Janus Kinase Inhibitors, Small Molecules

Which Trends Are Guiding The Direction Of The Crohn’s Disease (CD) Treatment Market?

Major companies operating within the Crohn’s disease (CD) treatment market are prioritizing the creation of advanced technologies, such as non-invasive biomarker-based diagnostic platforms, to improve disease detection, boost monitoring accuracy, and support individualized treatment decisions. Non-invasive diagnostic technologies for Crohn’s disease encompass tools that examine biological samples without requiring intrusive procedures, thereby allowing for earlier identification of inflammation, better tracking of disease activity, and an enhanced patient experience. For example, in March 2023, The IRR Chemistry Hub, an interdisciplinary research center based in Scotland, unveiled IBDSENSE, a fluorescence-based technology developed to enhance the diagnosis and monitoring of inflammatory bowel disease, which includes Crohn’s disease. The platform measures the enzyme activity of Granzyme B (GzmB) in patient biosamples, offering a patient-friendly, non-invasive method to assess disease progression and inform therapeutic choices.

Who Are The Companies Driving Activity In The Crohn’s Disease (CD) Treatment Market?

Major companies operating in the crohn’s disease (cd) treatment market are AbbVie Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited, Novartis AG, Amgen Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Mylan N.V., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Amneal Pharmaceuticals LLC, Ferring B.V., Eli Lilly and Company, Sanofi S.A., Bristol-Myers Squibb Company, Galapagos NV, Abivax, Biogen Inc., Gilead Sciences, RedHill Biopharma, Prometheus Biosciences, Hoffmann-La Roche

Get The Full Crohn’s Disease (CD) Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/crohns-disease-cd-treatment-global-market-report

Which Region Leads The Crohn’s Disease (CD) Treatment Market In Terms Of Market Share?

North America was the largest region in the Crohn’s disease (CD) treatment market in 2025. The regions covered in the crohn’s disease (cd) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Crohn’s Disease (CD) Treatment Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/crohns-disease-cd-treatment-global-market-report

Browse Through More Reports Similar to the Global Crohn’s Disease (CD) Treatment Market 2026, By The Business Research Company

Rare Inflammatory Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-inflammatory-disease-treatment-global-market-report

Crohns Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/crohns-disease-treatment-global-market-report

Inflammatory Bowel Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Forecasted Market Value Of The Crohn’s Disease (CD) Treatment Market Across 2026–2030?

Recent years have seen a steady expansion in the crohn’s disease (cd) treatment market size. The market is projected to expand from $12.32 billion in 2025 to reach $12.88 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 4.5%. This growth observed during the historic period is attributable to an increasing inflammatory bowel disease prevalence, limitations of conventional corticosteroids, hospital-centered disease management, delayed diagnosis rates, and reliance on immunomodulators.

The market for Crohn’s disease (CD) treatment is projected to experience robust expansion over the upcoming years, with an anticipated valuation of $16.01 billion by 2030, reflecting a compound annual growth rate (CAGR) of 5.6%. During the projected timeframe, this expansion is primarily driven by progress in biologics development, the rise of precision medicine, heightened patient awareness, enhanced diagnostic methodologies, and an uptick in specialized gastroenterology care. Key trends expected within this period encompass the escalating adoption of biologic therapies, the proliferation of targeted small molecule medications, a greater emphasis on achieving long-term disease remission, the development of personalized treatment strategies, and the incorporation of combination therapy protocols.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12902&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Crohn’s Disease (CD) Treatment Market?

The future expansion of the Crohn’s disease (CD) treatment market is anticipated to be driven by the rising occurrence of inflammatory bowel diseases. Inflammatory bowel disease (IBD) refers to a collection of persistent inflammatory conditions mainly impacting the gastrointestinal (GI) tract. Treatments for Crohn’s disease (CD) alleviate discomfort, reduce swelling, encourage periods of remission, and improve the general well-being of those affected by chronic inflammatory bowel disease. For example, the United States National Library of Medicine reported in September 2023 that in Canada, the incidence of inflammatory bowel diseases (IBD) was estimated at 30 per 100,000 person years in 2023, with an expected consistent annual increase of approximately 0.58%. By 2023, the prevalence of IBD in Canada reached approximately 825 per 100,000, with predictions that this figure could escalate to 1.1% of the population by 2035. Consequently, the growing prevalence of inflammatory bowel diseases propels the Crohn’s disease (CD) treatment market.

What Segmentation Levels Are Considered In The Crohn’s Disease (CD) Treatment Market?

The crohn’s disease (cd) treatment market covered in this report is segmented –

1) By Drug Type: Antibiotics, Amino Salicylates, Corticosteroids, Immunomodulators, Other Drug Types

2) By Route Of Administration: Oral, Injectable

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores

Subsegments:

1) By Antibiotics: Metronidazole, Ciprofloxacin, Rifaximin

2) By Amino Salicylates: Mesalamine, Sulfasalazine

3) By Corticosteroids: Prednisone, Budesonide, Hydrocortisone

4) By Immunomodulators: Azathioprine, Mercaptopurine, Methotrexate

5) By Other Drug Types: Biologic Therapies, Janus Kinase Inhibitors, Small Molecules

What Trends Are Projected To Affect The Crohn’s Disease (CD) Treatment Market?

Leading companies in the Crohn’s disease (CD) treatment market are prioritizing the creation of advanced technologies, particularly non-invasive biomarker-based diagnostic platforms, to elevate disease detection, sharpen monitoring accuracy, and aid in personalized treatment decisions. Non-invasive diagnostic technologies within Crohn’s disease are defined as instruments that examine biological samples without requiring invasive procedures, thereby facilitating earlier detection of inflammation, more effective tracking of disease activity, and an enhanced patient experience. For example, in March 2023, The IRR Chemistry Hub, an interdisciplinary research center located in Scotland, introduced IBDSENSE, a fluorescence-based technology developed to improve the diagnosis and monitoring of inflammatory bowel disease, including Crohn’s disease. This platform gauges the enzyme activity of Granzyme B (GzmB) in patient biosamples, presenting a patient-friendly, non-invasive technique to evaluate disease progression and inform therapeutic selections.

Which Leading Firms Are Contributing To The Growth Of The Crohn’s Disease (CD) Treatment Market?

Major companies operating in the crohn’s disease (cd) treatment market are AbbVie Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited, Novartis AG, Amgen Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Mylan N.V., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Amneal Pharmaceuticals LLC, Ferring B.V., Eli Lilly and Company, Sanofi S.A., Bristol-Myers Squibb Company, Galapagos NV, Abivax, Biogen Inc., Gilead Sciences, RedHill Biopharma, Prometheus Biosciences, Hoffmann-La Roche

Read the full crohn’s disease (cd) treatment market report here:

https://www.thebusinessresearchcompany.com/report/crohns-disease-cd-treatment-global-market-report

Which Regions Are Projected To Dominate The Crohn’s Disease (CD) Treatment Market In The Coming Years?

North America was the largest region in the Crohn’s disease (CD) treatment market in 2025. The regions covered in the crohn’s disease (cd) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Crohn’s Disease (CD) Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12902&type=smp

Browse Through More Reports Similar to the Global Crohn’s Disease (CD) Treatment Market 2026, By The Business Research Company

Acute Ischemic Stroke Diagnosis Global Market Report

https://www.thebusinessresearchcompany.com/report/acute-ischemic-stroke-diagnosis-global-market-report

Acute Ischemic Stroke Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/acute-ischemic-stroke-drugs-global-market-report

Myocardial Ischemia Global Market Report

https://www.thebusinessresearchcompany.com/report/myocardial-ischemia-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model